These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenic Westcott MM; Morse AE; Troy G; Blevins M; Wierzba T; Sanders JW Microbiol Spectr; 2024 Mar; 12(3):e0366123. PubMed ID: 38315025 [TBL] [Abstract][Full Text] [Related]
4. Reducing Recurrent Urinary Tract Infections in Women with MV140 Impacts Personal Burden of Disease: Secondary Analyses of a Randomized Placebo-controlled Efficacy Study. Curtis Nickel J; Foley S; Yang B; Casanovas M; Caballero R; Diez-Rivero CM; Lorenzo-Gómez MF Eur Urol Open Sci; 2024 May; 63():96-103. PubMed ID: 38585593 [TBL] [Abstract][Full Text] [Related]
5. Intracellular uropathogenic Escherichia coli are undetectable in urinary bladders after oral mecillinam treatment: An experimental study in a pig model of cystitis. Stærk K; Grønnemose RB; Palarasah Y; Lund L; Andersen TE Microb Pathog; 2022 Dec; 173(Pt A):105817. PubMed ID: 36244593 [TBL] [Abstract][Full Text] [Related]
6. A Combination of Polybacterial MV140 and Martin-Cruz L; Sevilla-Ortega C; Benito-Villalvilla C; Diez-Rivero CM; Sanchez-Ramón S; Subiza JL; Palomares O Front Immunol; 2020; 11():612269. PubMed ID: 33552074 [TBL] [Abstract][Full Text] [Related]
8. Secondary Analysis of Interstitial Cystitis/Bladder Pain Syndrome Patients Enrolled in a Recurrent Urinary Tract Infection Prevention Study Provides a Novel Paradigm for Etio-Pathogenesis and Practical Management of This Infection Phenotype. Nickel JC; Cotechini T; Doiron RC Pathogens; 2024 May; 13(5):. PubMed ID: 38787248 [TBL] [Abstract][Full Text] [Related]
9. Host restriction of Escherichia coli recurrent urinary tract infection occurs in a bacterial strain-specific manner. O'Brien VP; Dorsey DA; Hannan TJ; Hultgren SJ PLoS Pathog; 2018 Dec; 14(12):e1007457. PubMed ID: 30543708 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection. Habibi M; Asadi Karam MR; Bouzari S Microb Pathog; 2017 Sep; 110():477-483. PubMed ID: 28754265 [TBL] [Abstract][Full Text] [Related]
11. Metabolic Requirements of Escherichia coli in Intracellular Bacterial Communities during Urinary Tract Infection Pathogenesis. Conover MS; Hadjifrangiskou M; Palermo JJ; Hibbing ME; Dodson KW; Hultgren SJ mBio; 2016 Apr; 7(2):e00104-16. PubMed ID: 27073089 [TBL] [Abstract][Full Text] [Related]
12. VesiX cetylpyridinium chloride is rapidly bactericidal and reduces uropathogenic Sawant NV; Chang SS; Pandit KA; Khekare P; Warner WR; Zimmern PE; De Nisco NJ Microbiol Spectr; 2024 Mar; 12(3):e0271223. PubMed ID: 38240572 [TBL] [Abstract][Full Text] [Related]
13. Genome-wide analysis of fitness factors in uropathogenic Escherichia coli in a pig urinary tract infection model. García V; Stærk K; Alobaidallah MSA; Grønnemose RB; Guerra PR; Andersen TE; Olsen JE; Herrero-Fresno A Microbiol Res; 2022 Dec; 265():127202. PubMed ID: 36167007 [TBL] [Abstract][Full Text] [Related]
14. A Focus on Long-Term Follow-Up of Immunoprophylaxis to Recurrent Urinary Tract Infections: 10 Years of Experience with MV140 Vaccine in a Cohort of 1003 Patients Support High Efficacy and Safety. Ramírez Sevilla C; Gómez Lanza E; Llopis Manzanera J; Cetina Herrando A; Puyol Pallàs JM Arch Esp Urol; 2022 Nov; 75(9):753-757. PubMed ID: 36472057 [TBL] [Abstract][Full Text] [Related]
15. YbcL of uropathogenic Escherichia coli suppresses transepithelial neutrophil migration. Lau ME; Loughman JA; Hunstad DA Infect Immun; 2012 Dec; 80(12):4123-32. PubMed ID: 22966043 [TBL] [Abstract][Full Text] [Related]
16. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. Lorenzo-Gómez MF; Foley S; Nickel JC; García-Cenador MB; Padilla-Fernández BY; González-Casado I; Martínez-Huélamo M; Yang B; Blick C; Ferreira F; Caballero R; Saz-Leal P; Casanovas M NEJM Evid; 2022 Apr; 1(4):EVIDoa2100018. PubMed ID: 38319200 [TBL] [Abstract][Full Text] [Related]
17. Phenotypic Assessment of Clinical Escherichia coli Isolates as an Indicator for Uropathogenic Potential. Shea AE; Frick-Cheng AE; Smith SN; Mobley HLT mSystems; 2022 Dec; 7(6):e0082722. PubMed ID: 36445110 [TBL] [Abstract][Full Text] [Related]
18. Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection. Forsyth VS; Himpsl SD; Smith SN; Sarkissian CA; Mike LA; Stocki JA; Sintsova A; Alteri CJ; Mobley HLT mBio; 2020 Apr; 11(2):. PubMed ID: 32345645 [TBL] [Abstract][Full Text] [Related]
19. Rapid Bladder Interleukin-10 Synthesis in Response to Uropathogenic Escherichia coli Is Part of a Defense Strategy Triggered by the Major Bacterial Flagellar Filament FliC and Contingent on TLR5. Acharya D; Sullivan MJ; Duell BL; Goh KGK; Katupitiya L; Gosling D; Chamoun MN; Kakkanat A; Chattopadhyay D; Crowley M; Crossman DK; Schembri MA; Ulett GC mSphere; 2019 Nov; 4(6):. PubMed ID: 31776239 [TBL] [Abstract][Full Text] [Related]
20. CpxA Phosphatase Inhibitor Activates CpxRA and Is a Potential Treatment for Uropathogenic Escherichia coli in a Murine Model of Infection. Fortney KR; Smith SN; van Rensburg JJ; Brothwell JA; Gardner JJ; Katz BP; Ahsan N; Duerfeldt AS; Mobley HLT; Spinola SM Microbiol Spectr; 2022 Apr; 10(2):e0243021. PubMed ID: 35297652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]